CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Costs and expenses:
Research and development	$ 2,362	$ 5,443
General and administrative	2,726	3,525
Total operating expenses	5,088	8,968
Operating loss	(5,088)	(8,968)
Other income (expense):
Change in fair value of warrants potentially settleable in cash	3,892	(3,873)
Interest expense, net	(973)	(91)
Change In Fair Value Of Contingent Purchase Price Consideration	(113)	(170)
Total non-operating income (expense), net	2,806	(4,134)
Loss from continuing operations	(2,282)	(13,102)
Loss from discontinued operations	(9,436)	(3,391)
Net loss	$ (11,718)	$ (16,493)
Net loss per common share:
Basic and diluted net loss per share, continuing operations (in dollars per share)	$ (0.09)	$ (1.46)
Basic and diluted net loss per share, discontinued operations (in dollars per share)	(0.36)	(0.38)
Basic net loss per share (in dollars per share)	$ (0.45)	$ (1.84)
Weighted-average common shares outstanding: basic and diluted	26,406,356	8,968,616